RxDoctor Payments Data

Lawrence Vanmeter, MD

Internal Medicine · Newport Beach, CANPI 1639117948

Payments from drug & device makers

$804in general payments, 2019–2025

Across 40 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$104
  • Novo Nordisk$99
  • Astellas Pharma US Inc$94
  • Amgen$76
  • Pfizer$62
  • Boehringer Ingelheim$39
  • plus $330 from 14 others

What the payments were for

  • Food & beverage$804100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$804 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$422,402
Medicare patients
261
Services billed
12,915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$59,267
EliquisApixaban40$33,619
XareltoRivaroxaban26$23,754
JardianceEmpagliflozin11$12,720
MyrbetriqMirabegron26$11,975
PremarinEstrogens, Conjugated11$5,981
SynthroidLevothyroxine Sodium53$5,046
Eszopiclone26$3,616
Olmesartan Medoxomil114$2,735
Potassium Chloride53$2,590
Levothyroxine Sodium134$1,579
Colesevelam Hcl19$1,491
PaxlovidNirmatrelvir/Ritonavir20$1,429
Tamsulosin Hcl75$1,385
Clorazepate Dipotassium12$1,303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$99$59,26765 claims
PfizerEliquis, Premarin, Paxlovid$62$41,02971 claims
Boehringer IngelheimJardiance$39$12,72011 claims
Astellas Pharma US IncMyrbetriq$94$11,97526 claims
AbbVieSynthroid$19$5,04653 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →